Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00012259 · ClinicalTrials.gov registry record · Phase 2
Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia
A Phase 2 study, sponsored by Shire.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT00012259 is a Phase 2 study that has completed, run by Shire. The registered enrollment target is 31 participants.
The verdict
NCT00012259, a Phase 2 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of troxacitabine in treating patients who have blast phase chronic myelogenous leukemia.
Interventions
- DRUG troxacitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2000-12-11 |
| Est. Completion | 2002-03-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00012259
The ClinicalTrials.gov registry entry for NCT00012259 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which troxacitabine is the first listed.
NCT00012259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00012259 about?
NCT00012259 is a clinical study titled "Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of troxacitabine in treating patients who have blast phase chronic myelogenous leukemia.
What is the current status of trial NCT00012259?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2000-12-11. Estimated completion is 2002-03-27.
What interventions are being tested in trial NCT00012259?
The interventions under investigation include: troxacitabine (DRUG).
Who is sponsoring clinical trial NCT00012259?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.